Articles

https://www.latimes.com/science/story/2020-10-09/being-overweight-may-boost-risk-of-severe-covid-19-cdc-warns Adults who are overweight but not quite obese may face an increased risk of developing a severe case of COVID-19, according to new advice from the Centers for Disease Control and Prevention. The public health agency has long said that people who are obese are more likely to become severely ill if they have a coronavirus infection. The threat posed by being overweight is not as clear, but it was strong enough to be

https://www.nytimes.com/2020/09/28/well/live/the-underused-weight-loss-option-bariatric-surgery.html?auth=link-dismiss-google1tap&referringSource=articleShare PERSONAL HEALTH The Underused Weight Loss Option: Bariatric Surgery Experts say it can result in long-term weight loss and significantly improve physical and emotional health and even longevity. Credit…Gracia Lam Jane E. Brody By Jane E. Brody Sept. 28, 2020 394 Growing rates of obesity among Americans are clear evidence that even the best intentions and strongest motivations are often not enough to help seriously overweight people lose a significant amount of weight and,

2863 Hwy. 45 ByPass Frontage Rd. Jackson, TN 38305 This is the Jackson Clinic North Enter in Main entrance, elevators are to the right, take to second floor. First check in area to the left.

https://www.nike.com/ntc-app

http://youtube.com/planetfitness

http://www.businesswire.com/news/home/20160505005647/en/Allurion-Technologies%E2%80%99-Elipse%E2%84%A2-Intragastric-Balloon-Receives-Prestigious WELLESLEY, Mass.—(BUSINESS WIRE)—Allurion Technologies announced today that its flagship product, Elipse, has received the prestigious Emerging Technology Innovation Award from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Elipse is the world’s first procedureless™ intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is the first intragastric balloon to receive this award. Elipse received European Union CE marking in late 2015 and is now available at leading weight loss

FDA Approves Non-Surgical Solution ORBERA™ To Assist Patients With Weight Loss The U.S. Food and Drug Administration has approved the ORBERA™ Intragastric Balloon to assist adult patients suffering from obesity in losing and maintaining weight loss. Obesity affects more than 78.6 million U.S. adults and is one of the leading causes of preventable deaths in the U.S. In 2008, an estimated $147 billion was spent in medical costs for obesity. If obesity trends continue, it’s

FDA APPROVES THE RESHAPE™ INTEGRATED DUAL BALLOON SYSTEM, A FIRST-OF-ITS-KIND NON-SURGICAL WEIGHT LOSS PROCEDURE FOR PEOPLE WITH MILD TO MODERATE OBESITY • Next generation dual balloon designed to create a feeling of fullness while providing patient comfort and safety • Proven to provide more than twice the weight loss of diet and exercise alone • Procedure integrated with 12 months of medically-supervised nutrition and exercise coaching to help enable sustained weight loss SAN CLEMENTE, CALIF—DATE

ReShape Medical® Submits PMA Application to FDA for Non-Surgical Weight Loss Device ReShape™ Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum PR Newswire SAN CLEMENTE, Calif., July 1, 2014 SAN CLEMENTE, Calif., July 1, 2014 /PRNewswire/ — ReShape Medical® today announced that the Company has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the ReShape Integrated Dual Balloon System, the first and only dual

http://www.mcclatchydc.com/2014/06/29/231842/a-form-of-liver-disease-has-quickly.html PITTSBURGH — Renee Terney, who traveled to Erie, Pa., earlier this month to ride the slides at Splash Lagoon, has come a long way in the 2 1/2 years since she was struck by a form of liver disease that has quickly emerged as a public health threat and a challenge to transplant programs. Blood work and other tests revealed that the Sheraden resident had non-alcoholic fatty liver disease, an accumulation of fat in